SAN DIEGO--(BUSINESS WIRE)--
Retrophin, Inc. (NASDAQ:RTRX) today announced it will report fourth
quarter and full year 2014 financial results on Thursday, March 5, 2015
after the close of the U.S. financial markets. The Company will host a
conference call and webcast to discuss the financial results and provide
a general business update at 4:30 p.m. ET.
Conference Call Information
|
|
|
|
|
|
|
Date:
|
|
|
|
Thursday, March 5, 2015
|
|
Time:
|
|
|
|
4:30 p.m. ET
|
|
Dial-in numbers:
|
|
|
|
+1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International)
|
|
Confirmation code:
|
|
|
|
91191559
|
|
Live webcast:
|
|
|
|
www.retrophin.com
in the "Events & Presentations" section of the "Investors" page
|
|
|
|
|
|
|
A replay of the call will be available 7:30 p.m. ET, March 5, 2015 to
11:59 p.m. ET, March 12, 2015. The replay number is 855-859-2056 (U.S.)
or 404-537-3406 (International), confirmation code 91191559.
About Retrophin
Retrophin is a pharmaceutical company focused on the development,
acquisition and commercialization of drugs for the treatment of serious,
catastrophic or rare diseases for which there are currently no viable
options for patients. The Company's approved products include Chenodal®
and Thiola® and its pipeline includes compounds for several catastrophic
diseases, including focal segmental glomerulosclerosis (FSGS),
pantothenate kinase-associated neurodegeneration (PKAN), infantile
spasms, nephrotic syndrome and others. For additional information,
please visit www.retrophin.com.
Retrophin, Inc.
Chris Cline, CFA, 646-564-3680
Manager,
Investor Relations
IR@retrophin.com
Source: Retrophin, Inc.
News Provided by Acquire Media